Advertisement

Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients

  • Sylvia C. Kurz
  • David Schiff
  • Patrick Y. WenEmail author
Chapter
  • 472 Downloads

Abstract

Seizures are common in patients with brain tumors and may have a significant impact on quality of life. The actual seizure risk varies based on tumor histology and tumor location. Seizures are most common in patients with glioneuronal tumors and temporal, insular, or frontal lobe tumor location. Antiepileptic drug therapy is indicated in patients with a history of seizure, and the choice of symptomatic treatment should follow the principles of treatment for focal symptomatic epilepsy. In general, antiepileptic drugs that interact with the hepatic CYP450 co-enzymes should be avoided in brain tumor patients if possible due to potential drug-chemotherapy interactions. Levetiracetam represents the antiepileptic drug of choice in patients with brain tumors and has been demonstrated to be efficacious and is well tolerated in brain tumor patients. Lacosamide is an alternative anticonvulsant agent with increasing experience supporting its efficacy and favorable side effect profile.

Keywords

Epilepsy Seizure risk Brain tumors Gliomas Brain metastases Antiepileptic drug Levetiracetam Valproic acid Lacosamide 

References

  1. 1.
    Lote K, Stenwig AE, Skullerud K, Hirschberg H (1998) Prevalence and prognostic significance of epilepsy in patients with gliomas. Eur J Cancer 34:98–102CrossRefPubMedGoogle Scholar
  2. 2.
    Herman ST (2002) Epilepsy after brain insult: targeting epileptogenesis. Neurology 59:S21–S26CrossRefPubMedGoogle Scholar
  3. 3.
    De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E (2002) Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 43:175–182CrossRefPubMedGoogle Scholar
  4. 4.
    Southwell DG, Garcia PA, Berger MS, Barbaro NM, Chang EF (2012) Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 70:1406–1413; discussion 1413–1404CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chang EF, Christie C, Sullivan JE et al (2010) Seizure control outcomes after resection of dysembryoplastic neuroepithelial tumor in 50 patients. J Neurosurg Pediatr 5:123–130CrossRefPubMedGoogle Scholar
  6. 6.
    Tomita T, Volk JM, Shen W, Pundy T (2016) Glioneuronal tumors of cerebral hemisphere in children: correlation of surgical resection with seizure outcomes and tumor recurrences. Childs Nerv Syst 32:1839–1848CrossRefPubMedGoogle Scholar
  7. 7.
    Pallud J, Audureau E, Blonski M et al (2014) Epileptic seizures in diffuse low-grade gliomas in adults. Brain 137:449–462CrossRefGoogle Scholar
  8. 8.
    Chang EF, Potts MB, Keles GE et al (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235CrossRefPubMedGoogle Scholar
  9. 9.
    Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B (1995) The course of seizure disorders in patients with malignant gliomas. Arch Neurol 52:717–724CrossRefPubMedGoogle Scholar
  10. 10.
    Flanigan PM, Jahangiri A, Kuang R et al (2017) Improved survival with decreased wait time to surgery in glioblastoma patients presenting with seizure. Neurosurgery 81(5):824–833PubMedPubMedCentralGoogle Scholar
  11. 11.
    Toledo M, Sarria-Estrada S, Quintana M et al (2017) Epileptic features and survival in glioblastomas presenting with seizures. Epilepsy Res 130:1–6CrossRefPubMedGoogle Scholar
  12. 12.
    Englot DJ, Magill ST, Han SJ, Chang EF, Berger MS, McDermott MW (2016) Seizures in supratentorial meningioma: a systematic review and meta-analysis. J Neurosurg 124:1552–1561CrossRefPubMedGoogle Scholar
  13. 13.
    Lieu AS, Howng SL (2000) Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res 38:45–52CrossRefPubMedGoogle Scholar
  14. 14.
    Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W (2002) [The frequency of seizures in patients with primary brain tumors or cerebral metastases. An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna]. Wien Klin Wochenschr 114:911–916Google Scholar
  15. 15.
    Wu A, Weingart JD, Gallia GL et al (2017) Risk factors for preoperative seizures and loss of seizure control in patients undergoing surgery for metastatic brain tumors. World Neurosurg 104:120–128CrossRefPubMedGoogle Scholar
  16. 16.
    Lynam LM, Lyons MK, Drazkowski JF et al (2007) Frequency of seizures in patients with newly diagnosed brain tumors: a retrospective review. Clin Neurol Neurosurg 109:634–638CrossRefPubMedGoogle Scholar
  17. 17.
    You G, Sha ZY, Yan W et al (2012) Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study. Neuro Oncol 14:230–241CrossRefPubMedGoogle Scholar
  18. 18.
    Lee JW, Wen PY, Hurwitz S et al (2010) Morphological characteristics of brain tumors causing seizures. Arch Neurol 67:336–342PubMedPubMedCentralGoogle Scholar
  19. 19.
    Englot DJ, Chang EF, Vecht CJ (2016) Epilepsy and brain tumors. Handb Clin Neurol 134:267–285CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fish DR, Spencer SS (1995) Clinical correlations: MRI and EEG. Magn Reson Imaging 13:1113–1117CrossRefPubMedGoogle Scholar
  21. 21.
    Spencer S, Huh L (2008) Outcomes of epilepsy surgery in adults and children. Lancet Neurol 7:525–537CrossRefPubMedGoogle Scholar
  22. 22.
    Schaller B (2005) Influences of brain tumor-associated pH changes and hypoxia on epileptogenesis. Acta Neurol Scand 111:75–83CrossRefPubMedGoogle Scholar
  23. 23.
    Wolf HK, Roos D, Blumcke I, Pietsch T, Wiestler OD (1996) Perilesional neurochemical changes in focal epilepsies. Acta Neuropathol 91:376–384CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Beaumont A, Whittle IR (2000) The pathogenesis of tumour associated epilepsy. Acta Neurochir (Wien) 142:1–15CrossRefGoogle Scholar
  25. 25.
    Yuen TI, Morokoff AP, Bjorksten A et al (2012) Glutamate is associated with a higher risk of seizures in patients with gliomas. Neurology 79:883–889CrossRefPubMedGoogle Scholar
  26. 26.
    Rosati A, Poliani PL, Todeschini A et al (2013) Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme. Neuro Oncol 15:618–625CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Pallud J, Capelle L, Huberfeld G (2013) Tumoral epileptogenicity: how does it happen? Epilepsia 54(Suppl 9):30–34CrossRefPubMedGoogle Scholar
  28. 28.
    Aronica E, Yankaya B, Jansen GH et al (2001) Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumours from patients with intractable epilepsy. Neuropathol Appl Neurobiol 27:223–237CrossRefPubMedGoogle Scholar
  29. 29.
    Bateman DE, Hardy JA, McDermott JR, Parker DS, Edwardson JA (1988) Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 10:112–114CrossRefPubMedGoogle Scholar
  30. 30.
    Chen H, Judkins J, Thomas C et al (2017) Mutant IDH1 and seizures in patients with glioma. Neurology 88:1805–1813CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Blumcke I, Luyken C, Urbach H, Schramm J, Wiestler OD (2004) An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol 107:381–388CrossRefPubMedGoogle Scholar
  32. 32.
    Danfors T, Ribom D, Berntsson SG, Smits A (2009) Epileptic seizures and survival in early disease of grade 2 gliomas. Eur J Neurol 16:823–831CrossRefPubMedGoogle Scholar
  33. 33.
    Berendsen S, Varkila M, Kroonen J et al (2016) Prognostic relevance of epilepsy at presentation in glioblastoma patients. Neuro Oncol 18:700–706CrossRefPubMedGoogle Scholar
  34. 34.
    Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718CrossRefPubMedGoogle Scholar
  36. 36.
    Buckner JC, Shaw EG, Pugh SL et al (2016) Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N Engl J Med 374:1344–1355CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Cairncross JG, Wang M, Jenkins RB et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–790CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Stockhammer F, Misch M, Helms HJ et al (2012) IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom. Seizure 21:194–197CrossRefPubMedGoogle Scholar
  39. 39.
    Liubinas SV, D’Abaco GM, Moffat BM et al (2014) IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas. Epilepsia 55:1438–1443CrossRefPubMedGoogle Scholar
  40. 40.
    Neal A, Kwan P, O’Brien TJ, Buckland ME, Gonzales M, Morokoff A (2017) IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. Epilepsy Behav 78:30–36CrossRefPubMedGoogle Scholar
  41. 41.
    Chaichana KL, Parker SL, Olivi A, Quinones-Hinojosa A (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article. J Neurosurg 111:282–292CrossRefPubMedGoogle Scholar
  42. 42.
    Sheth RD (2002) Adolescent issues in epilepsy. J Child Neurol 17(Suppl 2):2S23–22S27CrossRefPubMedGoogle Scholar
  43. 43.
    Klein M, Engelberts NH, van der Ploeg HM et al (2003) Epilepsy in low-grade gliomas: the impact on cognitive function and quality of life. Ann Neurol 54:514–520CrossRefPubMedGoogle Scholar
  44. 44.
    Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168CrossRefPubMedGoogle Scholar
  45. 45.
    Batchelor TT, Byrne TN (2006) Supportive care of brain tumor patients. Hematol Oncol Clin North Am 20:1337–1361CrossRefPubMedGoogle Scholar
  46. 46.
    Auriel E, Landov H, Blatt I et al (2009) Quality of life in seizure-free patients with epilepsy on monotherapy. Epilepsy Behav 14:130–133CrossRefPubMedGoogle Scholar
  47. 47.
    Giulioni M, Galassi E, Zucchelli M, Volpi L (2005) Seizure outcome of lesionectomy in glioneuronal tumors associated with epilepsy in children. J Neurosurg 102:288–293PubMedPubMedCentralGoogle Scholar
  48. 48.
    Giulioni M, Gardella E, Rubboli G et al (2006) Lesionectomy in epileptogenic gangliogliomas: seizure outcome and surgical results. J Clin Neurosci 13:529–535CrossRefPubMedGoogle Scholar
  49. 49.
    Giulioni M, Rubboli G, Marucci G et al (2009) Seizure outcome of epilepsy surgery in focal epilepsies associated with temporomesial glioneuronal tumors: lesionectomy compared with tailored resection. J Neurosurg 111:1275–1282CrossRefPubMedGoogle Scholar
  50. 50.
    Bonney PA, Glenn CA, Ebeling PA et al (2015) Seizure freedom rates and prognostic indicators after resection of gangliogliomas: a review. World Neurosurg 84:1988–1996CrossRefPubMedGoogle Scholar
  51. 51.
    Bonney PA, Boettcher LB, Conner AK et al (2016) Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors. J Neurooncol 126:1–10CrossRefPubMedGoogle Scholar
  52. 52.
    Englot DJ, Han SJ, Berger MS, Barbaro NM, Chang EF (2012) Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors. Neurosurgery 70:921–928; discussion 928CrossRefPubMedGoogle Scholar
  53. 53.
    Bonney PA, Boettcher LB, Burks JD et al (2017) Rates of seizure freedom after surgical resection of diffuse low-grade gliomas. World Neurosurg 106:750–756CrossRefPubMedGoogle Scholar
  54. 54.
    Chaichana KL, Pendleton C, Zaidi H et al (2013) Seizure control for patients undergoing meningioma surgery. World Neurosurg 79:515–524CrossRefPubMedGoogle Scholar
  55. 55.
    Chen WC, Magill ST, Englot DJ et al (2017) Factors associated with pre- and postoperative seizures in 1033 patients undergoing supratentorial meningioma resection. Neurosurgery 81(2):297–306CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Ruda R, Magliola U, Bertero L et al (2013) Seizure control following radiotherapy in patients with diffuse gliomas: a retrospective study. Neuro Oncol 15:1739–1749CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Rogers LR, Morris HH, Lupica K (1993) Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 43:1599–1601CrossRefPubMedGoogle Scholar
  58. 58.
    Chalifoux R, Elisevich K (1996) Effect of ionizing radiation on partial seizures attributable to malignant cerebral tumors. Stereotact Funct Neurosurg 67:169–182CrossRefPubMedGoogle Scholar
  59. 59.
    Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6:937–944CrossRefGoogle Scholar
  60. 60.
    Koekkoek JA, Kerkhof M, Dirven L, Heimans JJ, Reijneveld JC, Taphoorn MJ (2015) Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro Oncol 17:924–934CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68:1831–1836CrossRefPubMedGoogle Scholar
  62. 62.
    Pace A, Vidiri A, Galie E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14:1722–1726CrossRefPubMedGoogle Scholar
  63. 63.
    Koekkoek JA, Dirven L, Heimans JJ et al (2015) Seizure reduction in a low-grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry 86:366–373CrossRefPubMedGoogle Scholar
  64. 64.
    Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43:1066–1073CrossRefPubMedGoogle Scholar
  65. 65.
    Lebrun C, Fontaine D, Bourg V et al (2007) Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur J Neurol 14:391–398CrossRefPubMedGoogle Scholar
  66. 66.
    Frenay MP, Fontaine D, Vandenbos F, Lebrun C (2005) First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol 12:685–690CrossRefPubMedGoogle Scholar
  67. 67.
    Wu AS, Trinh VT, Suki D et al (2013) A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg 118:873–883CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Franceschetti S, Binelli S, Casazza M et al (1990) Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wein) 103:47–51CrossRefGoogle Scholar
  69. 69.
    Forsyth PA, Weaver S, Fulton D et al (2003) Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30:106–112CrossRefPubMedGoogle Scholar
  70. 70.
    Dewan MC, White-Dzuro GA, Brinson PR et al (2017) The influence of perioperative seizure prophylaxis on seizure rate and hospital quality metrics following glioma resection. Neurosurgery 80:563–570CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    North JB, Penhall RK, Hanieh A, Frewin DB, Taylor WB (1983) Phenytoin and postoperative epilepsy. A double-blind study. J Neurosurg 58:672–677CrossRefPubMedGoogle Scholar
  72. 72.
    Chang SM, Parney IF, Huang W et al (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557–564CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Dewan MC, Thompson RC, Kalkanis SN, Barker FG II, Hadjipanayis CG (2017) Prophylactic antiepileptic drug administration following brain tumor resection: results of a recent AANS/CNS section on tumors survey. J Neurosurg 126:1772–1778CrossRefPubMedGoogle Scholar
  74. 74.
    Sirven JI, Wingerchuk DM, Drazkowski JF, Lyons MK, Zimmerman RS (2004) Seizure prophylaxis in patients with brain tumors: a meta-analysis. Mayo Clin Proc 79:1489–1494CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Pulman J, Greenhalgh J, Marson AG (2013) Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev 2:CD007286Google Scholar
  76. 76.
    Kuijlen JM, Teernstra OP, Kessels AG, Herpers MJ, Beuls EA (1996) Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 5:291–298CrossRefPubMedGoogle Scholar
  77. 77.
    Weston J, Greenhalgh J, Marson AG (2015) Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev 3:CD007286Google Scholar
  78. 78.
    Glantz MJ, Cole BF, Forsyth PA et al (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886–1893CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Soffietti R, Baumert BG, Bello L et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO task force. Eur J Neurol 17:1124–1133CrossRefPubMedGoogle Scholar
  80. 80.
    Glauser T, Ben-Menachem E, Bourgeois B et al (2013) Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 54:551–563CrossRefPubMedGoogle Scholar
  81. 81.
    Crepeau AZ, Sirven JI (2017) Management of adult onset seizures. Mayo Clin Proc 92:306–318CrossRefPubMedGoogle Scholar
  82. 82.
    Gilbert MR, Supko JG, Batchelor T et al (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940–2949PubMedGoogle Scholar
  83. 83.
    Maschio M, Albani F, Baruzzi A et al (2006) Levetiracetam therapy in patients with brain tumour and epilepsy. J Neurooncol 80:97–100CrossRefPubMedGoogle Scholar
  84. 84.
    Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol 2:404–409CrossRefPubMedGoogle Scholar
  85. 85.
    Oberndorfer S, Piribauer M, Marosi C, Lahrmann H, Hitzenberger P, Grisold W (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 72:255–260CrossRefPubMedGoogle Scholar
  86. 86.
    Neef C, de Voogd-van der Straaten I (1988) An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43:372–375CrossRefPubMedGoogle Scholar
  87. 87.
    Ruegg S (2002) Dexamethasone/phenytoin interactions: neurooncological concerns. Swiss Med Wkly 132:425–426PubMedGoogle Scholar
  88. 88.
    Lackner TE (1991) Interaction of dexamethasone with phenytoin. Pharmacotherapy 11:344–347PubMedGoogle Scholar
  89. 89.
    Pursche S, Schleyer E, von Bonin M et al (2008) Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol 3:198–203CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Raymond E, Brandes AA, Dittrich C et al (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26:4659–4665CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Wen PY, Yung WK, Lamborn KR et al (2006) Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12:4899–4907CrossRefPubMedGoogle Scholar
  92. 92.
    Maschio M, Dinapoli L, Sperati F et al (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104:205–214CrossRefPubMedGoogle Scholar
  93. 93.
    Usery JB, Michael LM II, Sills AK, Finch CK (2010) A prospective evaluation and literature review of levetiracetam use in patients with brain tumors and seizures. J Neurooncol 99:251–260CrossRefPubMedGoogle Scholar
  94. 94.
    Kerkhof M, Dielemans JC, van Breemen MS et al (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961–967CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Maschio M, Zarabla A, Maialetti A et al (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83–89CrossRefPubMedGoogle Scholar
  96. 96.
    Maschio M, Dinapoli L, Mingoia M et al (2011) Lacosamide as add-on in brain tumor-related epilepsy: preliminary report on efficacy and tolerability. J Neurol 258:2100–2104CrossRefPubMedGoogle Scholar
  97. 97.
    Brodie MJ, Whitesides J, Schiemann J, D’Souza J, Johnson ME (2016) Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: a pooled analysis from three phase III studies. Epilepsy Res 127:114–118CrossRefPubMedGoogle Scholar
  98. 98.
    Moseley BD, Sperling MR, Asadi-Pooya AA et al (2016) Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three phase III studies. Epilepsy Res 127:179–185CrossRefPubMedGoogle Scholar
  99. 99.
    Elger C, Koepp M, Trinka E et al (2017) Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: data from four double-blind placebo-controlled pivotal phase III clinical studies. CNS Neurosci Ther 23:961–972CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Plosker GL (2012) Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs 26:1085–1096CrossRefPubMedGoogle Scholar
  101. 101.
    French JA, Krauss GL, Biton V et al (2012) Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 79:589–596CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    French JA, Krauss GL, Steinhoff BJ et al (2013) Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia 54:117–125CrossRefPubMedGoogle Scholar
  103. 103.
    Krauss GL, Serratosa JM, Villanueva V et al (2012) Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 78:1408–1415CrossRefPubMedGoogle Scholar
  104. 104.
    Van Nifterik KA, Van den Berg J, Slotman BJ, Lafleur MV, Sminia P, Stalpers LJ (2012) Valproic acid sensitizes human glioma cells for temozolomide and gamma-radiation. J Neurooncol 107:61–67CrossRefPubMedGoogle Scholar
  105. 105.
    Hosein AN, Lim YC, Day B et al (2015) The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. J Neurooncol 122:263–271CrossRefPubMedGoogle Scholar
  106. 106.
    Chie EK, Shin JH, Kim JH, Kim HJ, Kim IA, Kim IH (2015) In vitro and in vivo radiosensitizing effect of valproic acid on fractionated irradiation. Cancer Res Treat 47:527–533CrossRefPubMedGoogle Scholar
  107. 107.
    Weller M, Gorlia T, Cairncross JG et al (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma. Neurology 77:1156–1164CrossRefPubMedPubMedCentralGoogle Scholar
  108. 108.
    Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86:504–509CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Happold C, Gorlia T, Chinot O et al (2016) Does valproic acid or levetiracetam improve survival in glioblastoma? A pooled analysis of prospective clinical trials in newly diagnosed glioblastoma. J Clin Oncol 34:731–739CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Bobustuc GC, Baker CH, Limaye A et al (2010) Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. Neuro Oncol 12:917–927CrossRefPubMedPubMedCentralGoogle Scholar
  111. 111.
    Kim YH, Kim T, Joo JD et al (2015) Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme. Cancer 121:2926–2932CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Sylvia C. Kurz
    • 1
  • David Schiff
    • 2
    • 3
    • 4
  • Patrick Y. Wen
    • 5
    Email author
  1. 1.Brain Tumor Center, Laura and Isaac Perlmutter Cancer CenterNew York University Langone HealthNew YorkUSA
  2. 2.Department of NeurologyUniversity of VirginiaCharlottesvilleUSA
  3. 3.Department of Neurological SurgeryUniversity of VirginiaCharlottesvilleUSA
  4. 4.Department of MedicineUniversity of VirginiaCharlottesvilleUSA
  5. 5.Center For Neuro-OncologyDana-Farber Cancer InstituteBostonUSA

Personalised recommendations